AXIOS December 8, 2023
Adriel Bettelheim

The Food and Drug Administration on Friday approved the first therapy based on CRISPR gene-editing technology to address the painful effects of sickle cell disease.

Why it matters: The technology could be applied beyond the estimated 100,000 Americans with sickle cell to other blood disorders like hemophilia, as well as certain cancers and infectious diseases.

  • But gene therapies are costly, with million-dollar price tags for some products, presenting huge challenges to employers, public health programs and other payers throughout the health system.
  • Morgan Stanley earlier this year projected the new sickle cell treatment could generate $19 billion in sales over the next decade.

Driving the news: The FDA approved Casgevy from Vertex Pharmaceuticals and CRISPR Therapeutics, a one-time...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
At Current Prices GLP-1s Aren’t Cost-Effective, Limiting Access To Patients
Latigo raises $150M to get non-opioid pain drugs through key tests
AstraZeneca Aims to Make Cell Therapy More Accessible With $425M EsoBiotec Acquisition
CMS doubles down on Medicare drug price negotiations
Drug shortages could surge 25% as AI reshapes specialty pharmacy: Survey

Share This Article